The Flow Study
The purpose of this study is to investigate a potential new treatment for thromboembolic diseases (blood clots). It is hoped that the study drug will reduce the risk of thromboembolic diseases that have lower risk of bleeding when compared to the existing treatments.
Thromboembolic diseases (blood clots) are the leading cause of death worldwide and are estimated to account for 1 in 4 deaths globally. Existing treatments for blood clots (anticoagulants) have the potential to increase the risk of bleeding, limiting the number of people who are able to receive treatment.
The study drug is designed to reduce the production of FXI, which is a component of the blood clotting process. Previous studies have shown that reducing the amount of FXI can prolong the time it takes for blood clots to form.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.